Setmelanotide

Imcivree

Setmelanotide (Imcivree) is a cyclic octapeptide MC4R-selective melanocortin agonist, developed by Rhythm Pharmaceuticals specifically for rare single-gene obesity disorders. It received FDA approval in 2020 for chronic weight management in patients with POMC, PCSK1, or LEPR deficiency, and in 2022 was extended to Bardet-Biedl syndrome. While it belongs to the same receptor family as PT-141, setmelanotide's engineering maximizes MC4R selectivity specifically to target the hypothalamic appetite pathway. Clinical trial data in patient populations shows dramatic weight reduction (approximately 10-25% depending on subtype) in conditions where lifestyle and other pharmacotherapies are ineffective. Because the approved indications are rare, setmelanotide is not a general obesity drug. Off-label interest exists for MC4R-pathway obesity phenotypes outside the approved genetic causes, but use is not recommended outside documented pathway defects.